Asset Details
Do you wish to reserve the book?
Mucin Expression Pattern in Pancreatic Diseases: Findings From EUS-Guided Fine-Needle Aspiration Biopsies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mucin Expression Pattern in Pancreatic Diseases: Findings From EUS-Guided Fine-Needle Aspiration Biopsies
Do you wish to request the book?
Mucin Expression Pattern in Pancreatic Diseases: Findings From EUS-Guided Fine-Needle Aspiration Biopsies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mucin Expression Pattern in Pancreatic Diseases: Findings From EUS-Guided Fine-Needle Aspiration Biopsies
2011
Overview
Alterations in mucin (MUC) glycosylation and expression have been described in cancer. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) can provide material for molecular biology analysis. This study assessed the feasibility of evaluating MUC expression from material obtained by EUS-FNA and studied the profile of MUC expression in benign and malignant pancreatic lesions.
A total of 90 patients with solid or cystic pancreatic lesions underwent FNA. The aspirated material was used for cytological analysis and RNA extraction to assess the expression pattern of MUCs by reverse transcription-PCR with primers specific for the MUC1, MUC2, MUC3, MUC4, MUC5A, MUC5B, MUC6, and MUC7 genes.
RNA extraction was successful in 81% of the biopsies. The prevalences of MUC1, MUC2, MUC4, and MUC7 in ductal adenocarcinoma were 57.7, 51.4, 18.9, and 73.0%, respectively. Fifty percent of benign lesions and neuroendocrine tumors (NETs), and 63% of intraductal papillary mucinous neoplasms (IPMNs) were positive for MUC1. Twenty-five percent of benign lesions, 86% of NETs, and 47% of IPMNs were positive for MUC2. Of NETs, 50% were positive for MUC1, and 14% were positive for MUC7. None of the benign lesions or NETs expressed MUC4. MUC7 expression was highly significant for adenocarcinoma (P=0.007) and borderline for IPMN (P=0.05). MUC7 was expressed in 37.5% of chronic pancreatitis cases.
RNA can be extracted from samples obtained under EUS-FNA. MUC7 could serve as a potential biological marker to identify malignant lesions, especially pancreatic adenocarcinoma.
Publisher
Nature Publishing Group,Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subject
/ Aged
/ Biological and medical sciences
/ Biomarkers, Tumor - genetics
/ Biomarkers, Tumor - metabolism
/ Biopsy, Fine-Needle - methods
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Investigative techniques, diagnostic techniques (general aspects)
/ Male
/ Neuroendocrine Tumors - genetics
/ Neuroendocrine Tumors - metabolism
/ Neuroendocrine Tumors - pathology
/ Pancreatic Neoplasms - genetics
/ Pancreatic Neoplasms - metabolism
/ Pancreatic Neoplasms - pathology
/ Pancreatic Pseudocyst - genetics
/ Pancreatic Pseudocyst - metabolism
/ Pancreatic Pseudocyst - pathology
/ Pancreatitis, Chronic - genetics
/ Pancreatitis, Chronic - metabolism
